The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.
The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.
复制标题
DOI：
10.1016/j.vaccine.2015.01.042
复制
发表时间：
2015-02-25
期刊：
影响因子：
5.5
通讯作者：
Cottingham MG
中科院分区：
文献类型：
--
作者：
Dicks MD;Guzman E;Spencer AJ;Gilbert SC;Charleston B;Hill AV;Cottingham MG
HAdV-5 (HAdV-C) vectors are more immunogenic than AdC68 or ChAdOx1 (HAdV-E) vectors in mice. In mice, CD8+ T cell responses peak later, and are more durable after HAdV-5 vaccination. In cattle, ChAdOx1 is at least as immunogenic as HAdV-5. Adenovirus vaccine vectors generated from new viral serotypes are routinely screened in pre-clinical laboratory animal models to identify the most immunogenic and efficacious candidates for further evaluation in clinical human and veterinary settings. Here, we show that studies in a laboratory species do not necessarily predict the hierarchy of vector performance in other mammals. In mice, after intramuscular immunization, HAdV-5 (Human adenovirus C) based vectors elicited cellular and humoral adaptive responses of higher magnitudes compared to the chimpanzee adenovirus vectors ChAdOx1 and AdC68 from species Human adenovirus E. After HAdV-5 vaccination, transgene specific IFN-γ+ CD8+ T cell responses reached peak magnitude later than after ChAdOx1 and AdC68 vaccination, and exhibited a slower contraction to a memory phenotype. In cattle, cellular and humoral immune responses were at least equivalent, if not higher, in magnitude after ChAdOx1 vaccination compared to HAdV-5. Though we have not tested protective efficacy in a disease model, these findings have important implications for the selection of candidate vectors for further evaluation. We propose that vaccines based on ChAdOx1 or other Human adenovirus E serotypes could be at least as immunogenic as current licensed bovine vaccines based on HAdV-5.
登录
查看更多内容
将腺病毒载体用作兽医疫苗。
影响因子：
5.1
作者：
Ferreira TB;Alves PM;Aunins JG;Carrondo MJ
通讯作者：
Carrondo MJ
影响因子：
5.4
作者：
Chen, H.;Xiang, Z. Q.;Ertl, H. C. J.
通讯作者：
Ertl, H. C. J.
影响因子：
5.5
作者：
Larsen, Karen Colbjorn;Spencer, Alexandra J.;Wyllie, David H.
通讯作者：
Wyllie, David H.
DOI：
10.1038/mt.2013.284
发表时间：
2014-03
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
--
作者：
通讯作者：
--
DOI：
10.4161/hv.6.1.10116
发表时间：
2010-01-01
期刊：
HUMAN VACCINES
影响因子：
--
作者：
Hill, Adrian V. S.;Reyes-Sandoval, Arturo;Draper, Simon J.
通讯作者：
Draper, Simon J.